MD TP22: Validation of a novel Biochip mosaic for the diagnosis of autoimmune bullous dermatoses

A Biochip mosaic based on indirect immunofluorescence has been developed for diagnosing autoimmune bullous dermatoses. Dermatology Biochip mosaics consist of different antigen substrates (monkey esophagus, primate salt-split skin, desmoglein 1 and 3, BP230 C-terminus and BP180 NC16A) and provide antibody profiles requiring only a single incubation. We will now validate a new mosaic with additional antigens (e.g. type VII collagen, rat bladder, monkey liver, gliadin-GAF3x) by analyzing about 800 serum samples collected worldwide from patients with pemphigus and pemphigoid disease to evaluate the clinical benefit.